REVIEW article
Front. Cell. Infect. Microbiol.
Sec. Veterinary and Zoonotic Infection
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1640352
This article is part of the Research TopicUnveiling Host-Pathogen Interactions: Insights into Animal Cellular Immunity and Novel Diagnostics - Volume IIView all 14 articles
Nanobodies in Animal Infectious Disease Control: Diagnosis and Therapy
Provisionally accepted
- Yibin Vocational and Technical College, Yibin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Animal infectious diseases threaten livestock productivity, public health, and food security. Traditional monoclonal antibodies (mAbs) face limitations in diagnostics and therapy due to their large size, instability, and high cost. Nanobodies (Nbs), derived from camelid heavy-chain antibodies, offer superior properties—small size (~15 kDa), high stability, deep tissue penetration, and cost-effective production. Nbs feature extended CDR3 loops, enabling access to cryptic epitopes, and exhibit exceptional thermal/pH stability. They are generated by immunizing camelids, cloning VHH genes, and screening via phage/yeast display. High-throughput methods (ELISA, flow cytometry) allow rapid isolation of high-affinity Nbs. Compared to mAbs, Nbs are economically produced in prokaryotic systems and engineered into multivalent or Fc-fused formats for enhanced efficacy. In diagnostics, Nbs enable sensitive, low-cost detection of pathogens like PRRSV, ASFV, and avian influenza. Nb-based competitive ELISAs and lateral flow assays improve field surveillance. Therapeutically, Nbs neutralize pathogens by targeting viral proteins (e.g., blocking PRRSV-CD163 entry) or bacterial toxins (e.g., Staphylococcus enterotoxins). Nb-Fc fusions degrade ASFV proteins via TRIM-away, while intracellular Nbs disrupt Mycobacterium ESAT-6 or Toxoplasma actin dynamics. Challenges remain in Nb affinity optimization, intracellular delivery, and in vivo half-life. Solutions include fusion with cell-penetrating peptides or viral vectors (e.g., adenoviruses). Reducing cross-species immunogenicity and scaling production are critical for broader adoption. With advances in protein engineering, Nbs hold transformative potential for preventing, diagnosing, and treating animal diseases, offering scalable solutions for global health and food security.
Keywords: nanobodies, Animal infectious diseases, diagnostics, Therapeutics, phage display, PRRSV, ASFV
Received: 03 Jun 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Wang, Tong and Qiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jing Wang, Yibin Vocational and Technical College, Yibin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.